Nicholas Theodosakis, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperpigmentation | 4 | 2024 | 112 | 3.220 |
Why?
|
Melanosis | 2 | 2024 | 78 | 1.700 |
Why?
|
Acne Vulgaris | 2 | 2023 | 302 | 1.300 |
Why?
|
International Classification of Diseases | 2 | 2022 | 867 | 1.170 |
Why?
|
Melanoma | 11 | 2023 | 5510 | 1.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2017 | 2043 | 0.680 |
Why?
|
Prenylation | 1 | 2018 | 37 | 0.660 |
Why?
|
Skin Neoplasms | 9 | 2023 | 5686 | 0.620 |
Why?
|
Tissue Embedding | 1 | 2016 | 43 | 0.570 |
Why?
|
Sepharose | 1 | 2016 | 108 | 0.550 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2017 | 337 | 0.530 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2018 | 5172 | 0.490 |
Why?
|
Alcoholism | 1 | 2024 | 1906 | 0.450 |
Why?
|
Cell Size | 1 | 2015 | 643 | 0.440 |
Why?
|
Tetracycline | 2 | 2023 | 214 | 0.430 |
Why?
|
Minocycline | 2 | 2023 | 163 | 0.410 |
Why?
|
Hair Removal | 1 | 2023 | 42 | 0.230 |
Why?
|
Glucose | 1 | 2015 | 4397 | 0.220 |
Why?
|
Proteomics | 1 | 2016 | 3638 | 0.220 |
Why?
|
Dermatology | 2 | 2024 | 872 | 0.220 |
Why?
|
Lung Neoplasms | 5 | 2022 | 13102 | 0.220 |
Why?
|
Doxycycline | 1 | 2023 | 326 | 0.210 |
Why?
|
Melanoma, Experimental | 2 | 2016 | 561 | 0.210 |
Why?
|
Endorphins | 1 | 2021 | 75 | 0.200 |
Why?
|
Mitochondria | 1 | 2014 | 3520 | 0.190 |
Why?
|
Cell Line, Tumor | 8 | 2018 | 16689 | 0.190 |
Why?
|
Hidradenitis Suppurativa | 1 | 2023 | 153 | 0.190 |
Why?
|
Cell Proliferation | 5 | 2018 | 10481 | 0.170 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 6773 | 0.160 |
Why?
|
Mevalonic Acid | 1 | 2018 | 42 | 0.160 |
Why?
|
Seasons | 1 | 2023 | 1493 | 0.150 |
Why?
|
Gender Identity | 1 | 2023 | 688 | 0.150 |
Why?
|
Pteridines | 1 | 2017 | 45 | 0.150 |
Why?
|
Humans | 35 | 2024 | 744343 | 0.150 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 56 | 0.150 |
Why?
|
Drug Synergism | 2 | 2018 | 1792 | 0.150 |
Why?
|
Mice, Nude | 3 | 2018 | 3689 | 0.140 |
Why?
|
5-Methylcytosine | 1 | 2017 | 154 | 0.140 |
Why?
|
Antimalarials | 1 | 2023 | 905 | 0.140 |
Why?
|
Azocines | 1 | 2015 | 18 | 0.140 |
Why?
|
Topoisomerase Inhibitors | 1 | 2015 | 18 | 0.140 |
Why?
|
RNA, Antisense | 1 | 2016 | 138 | 0.140 |
Why?
|
S-Adenosylmethionine | 1 | 2017 | 212 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 592 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2015 | 2016 | 0.130 |
Why?
|
Nevus, Pigmented | 1 | 2017 | 219 | 0.130 |
Why?
|
Hexokinase | 1 | 2015 | 125 | 0.130 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7181 | 0.120 |
Why?
|
Retrospective Studies | 8 | 2023 | 77449 | 0.120 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2016 | 338 | 0.120 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2015 | 261 | 0.120 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2018 | 1285 | 0.110 |
Why?
|
Azepines | 1 | 2015 | 336 | 0.110 |
Why?
|
Sexual Behavior | 1 | 2023 | 2057 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 3 | 2018 | 5535 | 0.110 |
Why?
|
Nevus | 1 | 2015 | 204 | 0.110 |
Why?
|
Cohort Studies | 4 | 2023 | 40561 | 0.110 |
Why?
|
Apoptosis | 4 | 2017 | 9727 | 0.110 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2014 | 252 | 0.110 |
Why?
|
Biological Products | 1 | 2021 | 860 | 0.110 |
Why?
|
Camptothecin | 1 | 2015 | 576 | 0.110 |
Why?
|
Antirheumatic Agents | 1 | 2022 | 1339 | 0.100 |
Why?
|
Taxoids | 1 | 2015 | 666 | 0.100 |
Why?
|
Multiprotein Complexes | 2 | 2016 | 1119 | 0.100 |
Why?
|
Immunoblotting | 1 | 2015 | 1682 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1758 | 0.100 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 1343 | 0.100 |
Why?
|
Microscopy | 1 | 2016 | 903 | 0.100 |
Why?
|
Adenocarcinoma | 4 | 2015 | 6364 | 0.100 |
Why?
|
Biological Transport | 1 | 2015 | 2118 | 0.090 |
Why?
|
Protein Processing, Post-Translational | 1 | 2018 | 1990 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2133 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3022 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3616 | 0.090 |
Why?
|
Triazoles | 1 | 2015 | 911 | 0.090 |
Why?
|
Metabolic Networks and Pathways | 1 | 2014 | 783 | 0.090 |
Why?
|
RNA Interference | 2 | 2016 | 2889 | 0.090 |
Why?
|
Benzhydryl Compounds | 1 | 2015 | 845 | 0.090 |
Why?
|
Esophageal Neoplasms | 2 | 2010 | 1583 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2109 | 0.080 |
Why?
|
DNA Methylation | 3 | 2017 | 4286 | 0.080 |
Why?
|
Signal Transduction | 5 | 2018 | 23403 | 0.080 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4149 | 0.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5221 | 0.080 |
Why?
|
Paclitaxel | 1 | 2015 | 1708 | 0.080 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3674 | 0.080 |
Why?
|
Colon | 1 | 2016 | 1772 | 0.080 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 6234 | 0.080 |
Why?
|
Databases, Factual | 1 | 2022 | 7729 | 0.080 |
Why?
|
Animals | 10 | 2021 | 168757 | 0.070 |
Why?
|
Mesoderm | 1 | 2010 | 686 | 0.070 |
Why?
|
Indoles | 1 | 2015 | 1839 | 0.070 |
Why?
|
Reactive Oxygen Species | 1 | 2014 | 2077 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2065 | 0.070 |
Why?
|
MicroRNAs | 3 | 2017 | 3752 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15226 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2024 | 21746 | 0.070 |
Why?
|
Sulfonamides | 1 | 2015 | 1938 | 0.070 |
Why?
|
Cadherins | 1 | 2010 | 907 | 0.070 |
Why?
|
Histone Deacetylases | 1 | 2010 | 728 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5867 | 0.060 |
Why?
|
Tumor Burden | 3 | 2016 | 1915 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2015 | 5974 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2010 | 4034 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3255 | 0.060 |
Why?
|
Genome, Human | 1 | 2016 | 4420 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2014 | 2899 | 0.050 |
Why?
|
Skin | 1 | 2016 | 4364 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 4851 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2016 | 5021 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11524 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7722 | 0.050 |
Why?
|
Disease Progression | 2 | 2016 | 13284 | 0.050 |
Why?
|
Insurance Carriers | 1 | 2023 | 157 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2009 | 2645 | 0.050 |
Why?
|
Melanocyte-Stimulating Hormones | 1 | 2021 | 25 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 21827 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5788 | 0.050 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2021 | 76 | 0.050 |
Why?
|
United States | 3 | 2024 | 69872 | 0.050 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2021 | 129 | 0.050 |
Why?
|
Hydroxychloroquine | 1 | 2023 | 412 | 0.040 |
Why?
|
Lasers | 1 | 2023 | 952 | 0.040 |
Why?
|
Massachusetts | 2 | 2021 | 8663 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2010 | 3690 | 0.040 |
Why?
|
Hair | 1 | 2021 | 483 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 12261 | 0.040 |
Why?
|
Outpatients | 1 | 2024 | 1486 | 0.030 |
Why?
|
Expressed Sequence Tags | 1 | 2016 | 255 | 0.030 |
Why?
|
Azacitidine | 1 | 2017 | 347 | 0.030 |
Why?
|
Retroelements | 1 | 2016 | 164 | 0.030 |
Why?
|
Mice, 129 Strain | 1 | 2016 | 386 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2017 | 8428 | 0.030 |
Why?
|
Transcription Factors | 1 | 2014 | 12208 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 20947 | 0.030 |
Why?
|
Female | 7 | 2024 | 380194 | 0.030 |
Why?
|
Epigenesis, Genetic | 2 | 2017 | 3647 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9239 | 0.030 |
Why?
|
Health Surveys | 1 | 2024 | 4037 | 0.030 |
Why?
|
Vitamins | 1 | 2021 | 1622 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2023 | 1901 | 0.030 |
Why?
|
Leadership | 1 | 2021 | 1357 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 21683 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 705 | 0.030 |
Why?
|
Mice | 4 | 2021 | 81183 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2015 | 611 | 0.020 |
Why?
|
Melanocytes | 1 | 2015 | 515 | 0.020 |
Why?
|
Male | 6 | 2024 | 350118 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 2987 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1157 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
Brain | 1 | 2016 | 26385 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2661 | 0.020 |
Why?
|
Genome | 1 | 2017 | 1808 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 192 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 3002 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 8642 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1708 | 0.020 |
Why?
|
Spheroids, Cellular | 1 | 2010 | 351 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3557 | 0.020 |
Why?
|
Vitamin D | 1 | 2021 | 3223 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2010 | 494 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2009 | 553 | 0.020 |
Why?
|
NF-kappa B | 1 | 2015 | 2499 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 6386 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2010 | 791 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2012 | 11031 | 0.020 |
Why?
|
Boronic Acids | 1 | 2010 | 965 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2012 | 1094 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2012 | 934 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2010 | 789 | 0.020 |
Why?
|
Cell Death | 1 | 2010 | 1706 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2924 | 0.010 |
Why?
|
Pyrazines | 1 | 2010 | 1230 | 0.010 |
Why?
|
Adult | 4 | 2024 | 214055 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2010 | 1338 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10943 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8388 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2010 | 2007 | 0.010 |
Why?
|
Risk Factors | 2 | 2024 | 72290 | 0.010 |
Why?
|
Transfection | 1 | 2010 | 5892 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 18111 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6895 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6538 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 40075 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2012 | 2728 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4217 | 0.010 |
Why?
|
Mutation | 2 | 2015 | 29786 | 0.010 |
Why?
|
Antigens, CD | 1 | 2010 | 4026 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 4420 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9274 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12245 | 0.010 |
Why?
|
Cell Movement | 1 | 2010 | 5217 | 0.010 |
Why?
|
Aged | 3 | 2021 | 163280 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 29063 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 3703 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 13033 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2009 | 57776 | 0.010 |
Why?
|
Prospective Studies | 1 | 2012 | 53288 | 0.000 |
Why?
|
Middle Aged | 2 | 2009 | 213383 | 0.000 |
Why?
|